Human tumor xenografts and mouse models of human tumors: re-discovering the models.
DOI: 10.1517/17460440903380430
关键词:
摘要: Background: Human tumor xenografts constitute the major efficacy and biology models for cancer drug discovery. Gene expression protein technologies have improved understanding of malignant diseases represented by human lines. Genetically engineered mouse (GEM) are improving allow assessment immune system-mediated therapeutics. Objective: The current brief review discusses status xenografts, GEM normal tissue assays used in Results: Preclinical Pediatric Tumor Program consortium with 47 molecularly well-characterized pediatric is leading field. Individual laboratory studies show no correlation between culture vivo characteristics some TRAMP RIP1TAG2 been studies. Recent often two mutated genes to greater genetic instability. Host cells important contributors ...
informahealthcare.com参考文章(111)
H.H Fiebig, A Maier, A.M Burger, Clonogenic assay with established human tumour xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery. European Journal of Cancer. ,vol. 40, pp. 802- 820 ,(2004) , 10.1016/J.EJCA.2004.01.009
Lisa M. Coussens, Gabriele Bergers, Douglas Hanahan, Angiogenesis and apoptosis are cellular parameters of neoplastic progression in transgenic mouse models of tumorigenesis. The International Journal of Developmental Biology. ,vol. 42, pp. 995- 1002 ,(1998) , 10.1387/IJDB.9853830
Kristan A. Keyes, Larry Mann, Karen Cox, Patti Treadway, Philip Iversen, Yun-Fei Chen, Beverly A. Teicher, Circulating angiogenic growth factor levels in mice bearing human tumors using Luminex Multiplex technology. Cancer Chemotherapy and Pharmacology. ,vol. 51, pp. 321- 327 ,(2003) , 10.1007/S00280-003-0572-5
Takashi Chishima, A. R. Moossa, Hiroshi Shimada, Robert M. Hoffman, Meng Yang, Ping Jiang, Yuying Tan, Xiaoen Wang, Satoshi Hasegawa, Widespread skeletal metastatic potential of human lung cancer revealed by green fluorescent protein expression. Cancer Research. ,vol. 58, pp. 4217- 4221 ,(1998)
Ronald A. Lubet, Gary Kelloff, Ernest T. Hawk, Kendra Tutsch, Carolyn E. Cole, Russell F. Jacoby, Michael A. Newton, Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos. Cancer Research. ,vol. 60, pp. 1864- 1870 ,(2000)
Peter J Houghton, Christopher L Morton, Chandra Tucker, Debbie Payne, Edward Favours, Claire Cole, Richard Gorlick, E Anders Kolb, Wendong Zhang, Richard Lock, Hernan Carol, Mimi Tajbakhsh, C Patrick Reynolds, John M Maris, Joshua Courtright, Stephen T Keir, Henry S Friedman, Charles Stopford, Joseph Zeidner, Jianrong Wu, Tiebin Liu, Catherine A Billups, Javed Khan, Sherry Ansher, Jian Zhang, Malcolm A Smith, None, The pediatric preclinical testing program: description of models and early testing results. Pediatric Blood & Cancer. ,vol. 49, pp. 928- 940 ,(2007) , 10.1002/PBC.21078
Alexander Kamb, What's wrong with our cancer models? Nature Reviews Drug Discovery. ,vol. 4, pp. 161- 165 ,(2005) , 10.1038/NRD1635
Emin Kuliyev, Norman Greenberg, Marjorie Steakley, Mitchell S. Steiner, Sharan Raghow, Efficacious Chemoprevention of Primary Prostate Cancer by Flutamide in an Autochthonous Transgenic Model Cancer Research. ,vol. 60, pp. 4093- 4097 ,(2000)
Michael C Bibby, Marie Suggitt, 50 Years of Preclinical Anticancer Drug Screening: Empirical to Target-Driven Approaches Clinical Cancer Research. ,vol. 11, pp. 971- 981 ,(2005)
Oren J. Becher, Eric C. Holland, Genetically Engineered Models Have Advantages over Xenografts for Preclinical Studies Cancer Research. ,vol. 66, pp. 3355- 3359 ,(2006) , 10.1158/0008-5472.CAN-05-3827